Monica Roberto Gadelha
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Centro de Ciências da Saúde
Unidade:
Faculdade de Medicina
Departamento:
Departamento de Clínica Médica/FM
Formação:
-
Universidade Federal do Rio de Janeiro
Medicina (Endocrinologia) | Doutorado | 1997 - 1998
-
Universidade Federal do Rio de Janeiro
Medicina (Endocrinologia) | Doutorado | 1996 - 1999
-
Universidade Federal do Rio de Janeiro
Medicina (Endocrinologia) | Mestrado | 1993 - 1995
-
Universidade Federal do Rio de Janeiro
Residência Médica em Endocrinologia e Metabologia | Especialização | 1990 - 1993
-
Universidade Federal do Rio de Janeiro
Faculdade de Medicina | Graduação | 1984 - 1989
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:
(65.28% artigos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| Epigenetic control of adamantinomatous craniopharyngiomas | 10.1210/clinem/dgae006 | 2024 |
| A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis | 10.1016/S2213-8587(23)00382-0 | 2024 |
| Diffusion-weighted imaging does not seem to be a predictor of consistency in pituitary adenomas | 10.1007/s11102-023-01377-6 | 2024 |
| Skeletal Muscle Evaluation in Patients With Acromegaly | 10.1210/jendso/bvae032 | 2024 |
| GH and prolactin co-secreting adenomas: it is time for a definition | 10.1210/clinem/dgae262 | 2024 |
| miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly | 10.3390/ijms24032875 | 2023 |
| A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly | 10.1007/s11102-022-01285-1 | 2023 |
| Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly | 10.1530/EC-23-0155 | 2023 |
| Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience | 10.1210/clinem/dgad378 | 2023 |
| Long-term efficacy and safety of osilodrostat in patients with Cushing?s disease: results from the LINC 4 study extension | 10.3389/fendo.2023.1236465 | 2023 |
| New Treatments for Acromegaly in Development | 10.1210/clinem/dgad568 | 2023 |
| Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement | 10.1038/s41574-023-00886-5 | 2023 |
| Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification | 10.1038/s41574-023-00883-8 | 2023 |
| Refractory somatotroph adenomas | 10.1007/s11102-023-01324-5 | 2023 |
| Importance of 24 h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings | 10.1007/s11102-023-01321-8 | 2023 |
| ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly | 10.1210/clinem/dgac643 | 2023 |
| Consensus on criteria for acromegaly diagnosis and remission | 10.1007/s11102-023-01360-1 | 2023 |
| Cushing's syndrome | 10.1016/S0140-6736(23)01961-X | 2023 |
| Alternative approach to BIPSS in the differential diagnosis of ACTH-dependent Cushing?s 2 syndrome | 2023 | |
| Biomarkers of response to treatment in acromegaly | 10.1080/17446651.2023.2293107 | 2023 |
| Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers | 10.1007/s11102-023-01345-0 | 2023 |
| Approach to the Patient: Differential Diagnosis of Cystic Sellar Lesions | 10.1210/clinem/dgac033 | 2022 |
| A prospective study on the efficacy of oral estrogen in female patients with acromegaly | 10.1007/s11102-021-01204-w | 2022 |
| Opioids and pituitary function: expert opinion | 10.1007/s11102-021-01202-y | 2022 |
| Randomized trial of osilodrostat for the treatment of Cushing?s disease | 10.1210/clinem/dgac178 | 2022 |
| MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands | 10.3390/ijms23158653 | 2022 |
| Acromegaly and Colorectal Neoplasm: An Update | 10.3389/fendo.2022.924952 | 2022 |
| Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report | 10.3389/fpsyt.2022.844718 | 2022 |
| Innovative therapeutics in acromegaly | 10.1016/j.beem.2022.101679 | 2022 |
| Telomere length and Wnt/β-catenin pathway in adamantinomatous craniopharyngiomas | 10.1530/eje-21-1269 | 2022 |
| Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases | 10.1210/clinem/dgac274 | 2022 |
| TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome | 10.1186/s40478-022-01437-1 | 2022 |
| The NETting of pituitary adenoma: a gland illusion | 10.1007/s11102-022-01235-x | 2022 |
| Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply | 10.1016/S2213-8587(22)00135-8 | 2022 |
| Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence? | 10.1210/clinem/dgac584 | 2022 |
| Characterization of sporadic somatotropinomas with high GIP receptor expression | 10.1007/s11102-022-01272-6 | 2022 |
| Pituitary acting drugs: cabergoline and pasireotide | 10.1007/s11102-022-01238-8 | 2022 |
| New and emerging pharmacological treatment options for acromegaly | 10.1080/14656566.2021.1908998 | 2021 |
| Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands | 10.1210/clinem/dgab125 | 2021 |
| Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? | 10.1210/jendso/bvaa205 | 2021 |
| Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study | 10.3389/fmed.2021.630982 | 2021 |
| Misinterpretation of viral load in COVID-19 clinical outcomes | 10.1016/j.virusres.2021.198340 | 2021 |
| Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement | 10.1007/s11102-021-01130-x | 2021 |
| The Glittre Activities of Daily Living Test in patients with acromegaly: Associations with hand function and health-related quality of life | 10.3233/bmr-200089 | 2021 |
| Identification of mutant K-RAS in pituitary macroadenoma | 10.1007/s11102-021-01151-6 | 2021 |
| GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil | 10.1007/s12020-021-02766-2 | 2021 |
| Apoplexy in sporadic pituitary adenomas: a single referral center experience and AIP mutation analysis | 10.20945/2359-3997000000358 | 2021 |
| Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism | 10.20945/2359-3997000000335 | 2021 |
| Cyclic ACTH-secreting thymic carcinoid: a case report and review of the literature | 10.20945/2359-3997000000346 | 2021 |
| gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly | 10.3390/cancers13194857 | 2021 |
| The future of somatostatin receptor ligands in acromegaly | 10.1210/clinem/dgab726 | 2021 |
| Prolactinomas | 10.1016/j.lpm.2021.104080 | 2021 |
| Consensus on diagnosis and management of Cushing's disease: a guideline update | 10.1016/s2213-8587(21)00235-7 | 2021 |
| Current opinion on the diagnosis and management of non-functioning pituitary adenomas | 10.1080/17446651.2021.1988851 | 2021 |
| Growth hormone-releasing hormone-secreting pulmonary neuroendocrine tumor associated with pituitary hyperplasia and somatotropinoma | 10.20945/2359-3997000000395 | 2021 |
| Pituitary MRI standard and advanced sequences: role in the diagnosis and characterization of pituitary adenomas | 10.1210/clinem/dgab901 | 2021 |
| Use of late-night salivary cortisol to monitor response to medical treatment in Cushing?s disease | 10.1530/EJE-19-0695 | 2020 |
| Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III (PAOLA) study | 10.1530/EJE-19-0762 | 2020 |
| Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs | 10.3389/fendo.2019.00931 | 2020 |
| Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors | 10.1210/clinem/dgaa040 | 2020 |
| A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas | 10.1007/s11102-019-01008-z | 2020 |
| Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly | 10.1007/s40618-019-01096-5 | 2020 |
| Letter to the Editor: -Our Response to COVID-19 as Endocrinologists and Diabetologists- | 10.1210/clinem/dgaa224 | 2020 |
| Cyclin A in nonfunctioning pituitary adenomas | 10.1007/s12020-020-02402-5 | 2020 |
| What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? | 10.1016/j.meegid.2020.104417 | 2020 |
| Telomerase expression in clinically non-functioning pituitary adenomas | 10.1007/s12020-020-02524-w | 2020 |
| Multidisciplinary management of acromegaly: A consensus | 10.1007/s11154-020-09588-z | 2020 |
| Acromegaly | 10.1016/j.ecl.2020.05.007 | 2020 |
| Risk factors and management of pasireotide-associated hyperglycemia in acromegaly | 10.1530/ec-20-0361 | 2020 |
| Novel therapies for acromegaly | 10.1530/ec-20-0433 | 2020 |
| A Pituitary Society update to acromegaly management guidelines | 10.1007/s11102-020-01091-7 | 2020 |
| Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles | 10.1038/s41598-018-37692-3 | 2019 |
| Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features | 10.3390/cancers11101439 | 2019 |
| Determinants of morbidities and mortality in acromegaly | 10.20945/2359-3997000000193 | 2019 |
| Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience | 10.1007/s12020-019-02149-8 | 2019 |
| Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas | 10.1111/cen.14133 | 2019 |
| A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update | 10.1210/clinem/dgz096 | 2019 |
| The effectiveness of a therapist-oriented home rehabilitation program for a patient with acromegaly: A case study | 10.1016/j.jbmt.2019.01.006 | 2019 |
| Brazilian multicenter study on pegvisomant treatment in acromegaly | 10.20945/2359-3997000000159 | 2019 |
| Physical exercise improves functional capacity and quality of life in patients with acromegaly: a 12-week follow-up study | 10.1007/s12020-019-02011-x | 2019 |
| Body self-image disturbances in women with prolactinoma | 10.1590/1516-4446-2018-0325 | 2019 |
| Clinical and functional variables can predict general fatigue in patients with acromegaly: an explanatory model approach | 10.20945/2359-3997000000127 | 2019 |
| Apoplexy in nonfunctioning pituitary adenomas | 10.1007/s11102-018-0870-x | 2018 |
| MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly | 10.1530/eje-17-1006 | 2018 |
| Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism | 10.20945/2359-3997000000032 | 2018 |
| A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism | 10.20945/2359-3997000000014 | 2018 |
| Predictors of surgical outcome and early criteria of remission in acromegaly | 10.1007/s12020-018-1590-8 | 2018 |
| Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands | 10.1111/cen.13595 | 2018 |
| Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly | 10.1111/jcmm.13427 | 2018 |
| Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial | 10.1016/s2213-8587(17)30326-1 | 2018 |
| Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson?s tumor | 10.1530/eje-17-0634 | 2018 |
| Systemic complications of acromegaly and the impact of the current treatment landscape: an update | 10.1210/er.2018-00115 | 2018 |
| Reply to -Predictors of surgical outcome and early criteria of remission in acromegaly-some controversial issues- | 10.1007/s12020-018-1732-z | 2018 |
| Somatostatin receptor ligands in the treatment of acromegaly | 10.1007/s11102-017-0791-0 | 2017 |
| The genetic background of acromegaly | 10.1007/s11102-017-0789-7 | 2017 |
| Acromegaly, a pituitary special issue | 10.1007/s11102-017-0790-1 | 2017 |
| Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. | 2017 | |
| AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation | 10.1530/ec-17-0237 | 2017 |
| Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic | 10.1007/s40618-017-0725-8 | 2017 |
| Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain | 10.1007/s11102-017-0795-9 | 2017 |
| Computed tomography airway lumen volumetry in patients with acromegaly: Association with growth hormone levels and lung function | 10.1111/1754-9485.12598 | 2017 |
| Balance Control and Peripheral Muscle Function in Aging: A Comparison Between Individuals with Acromegaly and Healthy Subjects | 10.1123/japa.2016-0100 | 2017 |
| Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event | 10.1159/000446542 | 2017 |
| Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment | 10.1007/s11102-016-0749-7 | 2016 |
| Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response | 10.1590/2359-3997000000210 | 2016 |
| A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism | 10.1590/2359-3997000000179 | 2016 |
| Recommendations of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism for the diagnosis of Cushing?s disease in Brazil | 10.1590/2359-3997000000174 | 2016 |
| Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study | 10.1186/s12902-016-0096-8 | 2016 |
| Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients | 10.1007/s11102-016-0715-4 | 2016 |
| Challenges in the diagnosis and management of acromegaly: a focus on comorbidities | 10.1007/s11102-016-0725-2 | 2016 |
| Parameters of knee isokinetic dynamometry in individuals with acromegaly: Association with growth hormone levels and general fatigue | 10.3233/ies-160635 | 2016 |
| Evidence-based guidelines in acromegaly: implications on the clinic | 10.1586/17446651.2016.1145051 | 2016 |
| Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly | 10.1007/s12020-016-0895-8 | 2016 |
| Pituitary Tumor Management in Pregnancy | 10.1016/j.ecl.2014.10.015 | 2015 |
| Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas | 10.1371/journal.pone.0117107 | 2015 |
| Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas | 10.1016/j.canlet.2015.01.037 | 2015 |
| Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly | 10.1590/1414-431x20154786 | 2015 |
| Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in Mutation Carriers | 10.1210/jc.2015-1869 | 2015 |
| Lanreotide Autogel 120-mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study | 10.1530/EJE-15-0215 | 2015 |
| Current reliability of the Immulite® assay for measurement of serum IGF-1 in the Brazilian adult population | 10.1590/2359-3997000000035 | 2015 |
| Adverse effects of glucocorticoids: coagulopathy | 10.1530/eje-15-0198 | 2015 |
| Ipilimumab-induced hypophysitis: review of the literature | 10.1007/s40618-015-0301-z | 2015 |
| The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease | 10.1210/jc.2015-1453 | 2015 |
| What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients? | 10.1589/jpts.27.719 | 2015 |
| Insulin-like growth factor (IgF)-I, IgF binding protein-3, and prostate cancer: correlation with gleason score | 10.1590/s1677-5538.ibju.2015.01.15 | 2015 |
| Pasireotide for the treatment of acromegaly | 10.1517/14656566.2016.1146688 | 2015 |
| Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort | 10.1210/jc.2015-2675 | 2015 |
| Low risk of coronary artery disease in patients with acromegaly | 10.1007/s12020-015-0628-4 | 2015 |
| Bone density and microarchitecture in endogenous hypercortisolism | 10.1111/cen.12812 | 2015 |
| A paradigm shift in the medical treatment of acromegaly: from a -trial-and-error- to a personalized therapeutic decision-making process | 10.1111/cen.12797 | 2015 |
| Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly | 10.1007/s11102-015-0684-z | 2015 |
| Efficacy of medical treatment in Cushing's disease: a systematic review | 10.1111/cen.12345 | 2014 |
| Aggressive tumors and difficult choices in acromegaly | 10.1007/s11102-013-0538-5 | 2014 |
| The role of primary pharmacological therapy in acromegaly | 10.1007/s11102-013-0530-0 | 2014 |
| A 21-Year-Old Female with Galactorrhea | 10.1111/bpa.12139 | 2014 |
| Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease | 10.1530/EJE-13-1013 | 2014 |
| Posture and balance control in patients with acromegaly: Results of a cross-sectional study | 10.1016/j.gaitpost.2014.03.014 | 2014 |
| Cabergoline treatment in acromegaly: cons | 10.1007/s12020-014-0183-4 | 2014 |
| Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial | 10.1016/s2213-8587(14)70169-x | 2014 |
| Rotation thromboelastometry and the hypercoagulable state in Cushing's Syndrome | 10.1111/cen.12491 | 2014 |
| Dopamine receptor subtype 2 expression profile in non-functioning pituitary adenomas and in vivo response to cabergoline therapy | 10.1111/cen.12684 | 2014 |
| Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs | 2013 | |
| Lycopene and Beta-Carotene Induce Growth Inhibition and Proapoptotic Effects on ACTH-Secreting Pituitary Adenoma Cells | 10.1371/journal.pone.0062773 | 2013 |
| Acromegaly Has a Negative Influence on Trabecular Bone, But Not on Cortical Bone, as Assessed by High-Resolution Peripheral Quantitative Computed Tomography | 10.1210/jc.2012-4073 | 2013 |
| Vertebral Fracture Assessment in Acromegaly | 10.1016/j.jocd.2012.06.002 | 2013 |
| Prostatic disorders in acromegalic patients experience of a Brazilian center | 2013 | |
| The Role of Temozolomide in the Treatment of a Patient with a Pure Silent Pituitary Somatotroph Carcinoma | 10.4158/ep12400.cr | 2013 |
| Ki-67 is a predictor of acromegaly control with octreotide-LAR independent of SSTR2 status and relates to cytokeratin pattern | 10.1530/eje-13-0349 | 2013 |
| Functional evaluation of the joints in acromegalic patients and associated factors | 10.1007/s10067-013-2219-1 | 2013 |
| Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists | 10.1007/s11102-013-0524-y | 2013 |
| ZAC1 and SSTR2 Are Downregulated in Non-Functioning Pituitary Adenomas but Not in somatotropinomas | 10.1371/journal.pone.0077406 | 2013 |
| On the Functional Capacity and Quality of Life of Patients with Acromegaly: Are They Candidates for Rehabilitation Programs? | 10.1589/jpts.25.1497 | 2013 |
| Pulmonary function testing and chest tomography in patients with acromegaly | 10.1186/2049-6958-8-70 | 2013 |
| Acromegaly and pregnancy: a prospective study | 10.1530/eje-13-0460 | 2013 |
| Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center | 2013 | |
| MicroRNAs: Suggested role in pituitary adenoma pathogenesis | 2013 | |
| Giant prolactinomas: the therapeutic approach | 10.1111/cen.12242 | 2013 |
| Pasireotide versus octreotide in acromegaly: a head-to-head superiority study | 10.1210/jc.2013-2480 | 2013 |
| A 12-month phase 3 study of pasireotide in Cushing's disease | 10.1056/NEJMoa1105743 | 2012 |
| Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry | 2012 | |
| Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression | 10.1590/s0004-27302012000800007 | 2012 |
| A Subcutaneous Octreotide Hydrogel Implant for the Treatment of Acromegaly | 10.4158/EP11388.OR | 2012 |
| AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression | 10.1530/erc-12-0020 | 2012 |
| Association of Dengue Hemorrhagic Fever with Multiple Risk Factors for Pituitary Apoplexy | 10.4158/EP11341.CR | 2012 |
| Growth of an aggressive tumor during pregnancy in an acromegalic patient | 10.1507/endocrj.ej11-0306 | 2012 |
| Acromegalic patients lost to follow-up: a pilot study | 10.1007/s11102-012-0412-x | 2012 |
| Novel pathway for somatostatin analogs in patients with acromegaly | 10.1016/j.tem.2012.11.007 | 2012 |
| Impact of gsp Oncogene on the mRNA Content for Somatostatin and Dopamine Receptors in Human Somatotropinomas | 10.1159/000322040 | 2011 |
| Recomendações do Departamento de Neuroendocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento da acromegalia no Brasil | 10.1590/S0004-27302011000200001 | 2011 |
| Low Aryl Hydrocarbon Receptor-Interacting Protein Expression Is a Better Marker of Invasiveness in Somatotropinomas than Ki-67 and p53 | 10.1159/000322787 | 2011 |
| Recomendações do Departamento de Neuroendocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o Diagnóstico e Tratamento da Acromegalia no Brasil | 10.1590/S0004-27302011000900011 | 2011 |
| Aortic root ectasia in patients with acromegaly: experience at a single center | 10.1111/j.1365-2265.2011.04067.x | 2011 |
| Pathogenesis of familial acromegaly | 2010 | |
| Serum levels of 20K-hGH and 22K-hGH isoforms in acromegalic patients | 2010 | |
| Germ cell tumor presenting as sellar mass with suprasellar extension and long history of hypopituitarism | 2010 | |
| Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families | 10.1002/humu.21292 | 2010 |
| Management of prolactinomas in Brazil: an electronic survey | 10.1007/s11102-010-0217-8 | 2010 |
| Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR | 10.1016/j.ghir.2009.10.001 | 2010 |
| Management of acromegaly in Latin America: expert panel recommendations | 10.1007/s11102-009-0206-y | 2010 |
| Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening | 10.1590/S0004-27302010000800006 | 2010 |
| BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists | 10.1038/oby.2010.150 | 2010 |
| Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly | 10.1007/s00198-009-1165-x | 2010 |
| Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly | 10.1210/jc.2008-1826 | 2009 |
| Hematologic neoplasias and acromegaly | 10.1007/s11102-009-0176-0 | 2009 |
| Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study | 10.1111/j.1365-2265.2008.03441.x | 2009 |
| Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience | 10.1007/s11102-008-0136-0 | 2009 |
| IGF-I, insulin and prostate cancer | 10.1590/S0004-27302009000800010 | 2009 |
| Prostate cancer and acromegaly | 10.1590/S0004-27302009000800009 | 2009 |
| Utility of [18F] fluoro-2-deoxy-d-glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors | 10.1007/s11102-008-0125-3 | 2009 |
| Avaliação do metabolismo da glicose em pacientes acromegálicos antes e após tratamento com octreotide LAR | 10.1590/S0004-27302008000100009 | 2008 |
| Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR | 10.1530/EJE-07-0562 | 2008 |
| The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas | 10.1210/jc.2007-2611 | 2008 |
| Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. | 10.1530/EJE-07-0753 | 2008 |
| Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR® | 10.1016/j.ghir.2008.02.001 | 2008 |
| Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline | 10.1007/s11102-007-0046-6 | 2008 |
| Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients | 2008 | |
| Transient central diabetes insipidus followed by pituitary apoplexy treated in a conservative way | 2008 | |
| Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR® responsiveness in acromegaly | 10.1590/S0004-27302008000800014 | 2008 |
| Sellar and suprasellar mixed germ cell tumor mimicking a pituitary adenoma | 10.1007/s11102-008-0161-z | 2008 |
| QUANTITATIVE ANALYSIS OF SOMATOSTATIN RECEPTOR SUBTYPE (SSTR1-5) GENE EXPRESSION LEVELS IN SOMATOTROPINOMAS AND NON-FUNCTIONING PITUITARY ADENOMAS | 2007 | |
| TWO HOUR MEAN GH IS NOT SUPERIOR TO BASAL GH FOR THE FOLLOW UP OF ACROMEGALIC PATIENTS TREATED WITH OCTREOTIDE LAR | 2007 | |
| ACROMEGALY SECONDARY TO GROWTH HORMONE-RELEASING HORMONE SECRETED BY AN INCIDENTALLY DISCOVERED PHEOCHROMOCYTOMA | 2007 | |
| NOVEL VASOPRESSIN TYPE 2 (AVPR2) GENE MUTATIONS IN BRAZILIAN NEPHROGENIC DIABETES INSIPIDUS PATIENTS | 2006 | |
| CARDIAC MORPHOLOGY AND PERFORMANCE ALTERATIONS AND ANALYSIS OF DETERMINANT FACTORS OF LEFT VENTRICULAR HYPERTROPHY IN 40 PATIENTS WITH ACROMEGALY | 2006 | |
| OSTEOSARCOMA AND ACROMEGALY: CASE REPORT AND REVIEW OF THE LITERATURE | 2006 | |
| BRAZILIAN EXPERIENCE IN THE TREATMENT OF 250 ACROMEGALIC PATIENTS WITH SANDOSTATIN LAR | 2005 | |
| MEDICAL THERAPY OF ACROMEGALY WITH AN OCTREOTIDE SUBDERMAL IMPLANT | 2005 | |
| OBSERVATIONAL STUDY FOR EVALUATION OF QoL OF ACROMEGALIC PATIENTS IN USE OF SANDOSTATIN LAR | 2005 | |
| EXPRESSION OF RETINOBLASTOMA PROTEIN IN HUMAN GROWTH HORMONE-SECRETING PITUITARY ADENOMAS | 2005 | |
| TESTE AGUDO COM OCTREOTIDE SUBCUTÂNEO COMO PREDITOR DE RESPOSTA AO TRATAMENTO COM OCTREOTIDE LAR | 2005 | |
| TUMOR DELETION MAPPING OF CHROMOSOMAL REGION 13q14 IN 43 GROWTH HORMONE SECRETING PITUITARY ADENOMAS | 2005 | |
| Etiologic aspects and management of acromegaly | 10.1590/S0004-27302005000500004 | 2005 |
| DEPENDENCY AND ANALGESIA RELATED TO THE TREATMENT WITH SUBCUTANEOUS OCTREOTIDE IN PATIENTS WITH GROWTH HORMONE-SECRETING TUMORS | 2004 | |
| A MEIOTIC RECOMBINATION IN A NEW ISOLATED FAMILIAL SOMATOTROPINOMA KINDRED | 2004 | |
| DOENÇA TIREOIDEANA COM AUTO-ANTICORPOS NEGATIVOS APÓS CURA DE DOENÇA DE CUSHING: RELATO DE DOIS CASOS | 2004 | |
| PSEUDOTUMOR INFLAMATÓRIO DE REGIÃO SELAR E PARA-SELAR: RELATO DE UM CASO | 2004 | |
| AUSÊNCIA DE MUTAÇÃO NO GENE HESX1 EM CASO DE DISPLASIA SEPTO-ÓPTICA | 2004 | |
| EFETIVIDADE DO OCTREOTIDE LAR NO TRATAMENTO DA ACROMEGALIA - EXPERIÊNCIA DO HUCFF/UFRJ | 2004 | |
| AVALIAÇÃO CARDIOVASCULAR NA ACROMEGALIA | 2004 | |
| IDENTIFICAÇÃO DO NOVO INTERVALO GENÉTICO DE 3,88 MB EM 11Q13 E ANÁLISE DE GENES CANDIDATOS POR CDNA MICROARRAY EM SOMATOTROPINOMAS ESPORÁDICOS | 2004 | |
| ANÁLISE CLÍNICA, LABORATORIAL E DENSITOMÉTRICA DE TRINTA HOMENS COM PROLACTINOMA | 2004 | |
| INFLUENCE OF TESTOSTERONE ON BONE MINERAL DENSITY OF MEN WITH PROLACTINOMA | 2004 | |
| BASES MOLECULARES DOS ADENOMAS HIPOFISÁRIOS COM ÊNFASE NOS SOMATOTROPINOMAS | 2004 | |
| EFETIVIDADE DO OCTREOTIDE LAR NO TRATAMENTO DA ACROMEGALIA | 2004 | |
| VALOR DO TESTE AGUDO NA PREDIÇÃO DA RESPOSTA AO TRATAMENTO COM OCTREOTIDE LAR | 2004 | |
| REDUÇÃO DO VOLUME TUMORAL COM OCTREOTIDE LAR NA ACROMEGALIA | 2004 | |
| EFEITO DE 6 MESES DE TRATAMENTO COM OCTREOTIDE LAR NA FUNÇÃO CARDIOVASCULAR EM PACIENTES ACROMEGÁLICOS | 2004 | |
| FATORES PREDITORES PARA HIPERTROFIA VENTRICULAR ESQUERDA NA ACROMEGALIA | 2004 | |
| NÍVEIS DE GH E IGF-I DISCORDANTES EM ACROMEGÁLICOS | 2004 | |
| CAVERNOUS CAROTID ARTERY PSEUDO-ANEURYSM TREATED BY STENTING IN ACROMEGALIC PATIENT | 2003 | |
| OPTIC PATHWAYS TUBERCULOMA MIMICKING GLIOMA: CASE REPORT | 2003 | |
| ACROMEGALY SECONDARY TO ECTOPIC GROWTH HORMONE-RELEASING HORMONE-SECRETING BRONCHIAL CARCINOID CURED AFTER PNEUMECTOMY | 2003 | |
| DIAGNÓSTICO E TRATAMENTO DA ACROMEGALIA NO BRASIL | 2003 | |
| ARMADILHAS NO DIAGNÓSTICO DA HIPERPROLACTINEMIA | 2003 | |
| TUMOR DELETION MAP OF CHROMOSOME REGION 13Q12-14 IN 40 GH-SECRETING ADENOMAS | 2003 | |
| ASPECTOS CLÍNICOS E TERAPÊUTICOS DE PROLACTINOMAS EM HOMENS | 2003 | |
| PROLACTINOMA NO SEXO MASCULINO: APRESENTAÇÃO CLÍNICA, LABORATORIAL E NEURORRADIOLÓGICA | 2002 | |
| VARIAÇÃO DE NÍVEIS DE PROLACTINA E PERCENTUAL DE USO DE LEVOTIROXINA, TESTOSTERONA E PREDNISONA CONFORME O TIPO DE TERAPIA EM HOMENS COM PROLACTINOMA | 2002 | |
| ADENOMA HIPOFISÁRIO PRODUTOR DE GH SEM CLÍNICA DE ACROMEGALIA | 2002 | |
| ANEURISMA IATROGÊNICO CAROTÍDEO APÓS ACESSO TRANSESFENOIDAL EM ACROMEGALIA: TRATAMENTO ENDOVASCULAR COM STENT E CONSIDERAÇÕES ANATÔMICAS | 2002 | |
| ACROMEGALIA SECUNDÁRIA A SECREÇÃO ECTÓPICA DE GHRH CURADA APÓS RESSECÇÃO DE TUMOR CARCINÓIDE DE PULMÃO | 2002 | |
| ANÁLISE DE INSTABILIDADE DE MICROSSATÉLITES E CORRELAÇÃO CLÍNICA EM PACIENTES COM SOMATOTROPINOMAS ESPORÁDICOS | 2002 | |
| ANÁLISE DA PERDA DO ESTADO HETEROZIGOTO (LOH) NOS SOMATOTROPINOMAS ESPORÁDICOS UTILIZANDO MICROSSATÉLITES POLIMÓRFICOS DA REGIÃO CROMOSSÔMICA 11Q13 E SUA CORRELAÇÃO CLÍNICA | 2002 | |
| DEPENDÊNCIA E ANALGESIA EM ACROMEGÁLICOS TRATADOS COM ALTAS DOSES DE OCTREOTIDE | 2002 | |
| INFLUÊNCIA DOS NÍVEIS DE PROLACTINA E TAMANHO TUMORAL NA RECUPERAÇÃO PÓS OPERATÓRIA DA FUNÇÃO HIPOFISÁRIA EM MACROADENOMAS HIPOFISÁRIOS CLINICAMENTE NÃO FUNCIONANTES | 2002 | |
| VALOR DO TESTE LIDDLE II NO DIAGNÓSTICO DE DOENÇA DE CUSHING | 2002 | |
| CRIPTOCOCOSE PSEUDOTUMORAL EM PACIENTE COM DOENÇA DE CUSHING | 2002 | |
| AVALIAÇÃO DE MICROSSATÉLITES POLIMÓRFICOS INTRA E EXTRAGÊNICOS DO RB1 NO CROMOSSOMA 13Q EM ADENOMAS HIPOFISÁRIOS PRODUTORES DE GH | 2002 | |
| Diagnóstico diferencial entre tumor primário do sistema nervoso central, radionecrose e metástases de macroprolactinoma invasivo: Papel das técnicas avaçadas de ressonância magnética | 2002 | |
| DELEÇÕES ALÉLICAS NA REGIÃO CROMOSSÔMICA 11Q13.1-Q13.3 EM ADENOMAS HIPOFISÁRIOS ESPORÁDICOS SECRETORES DE GH | 2002 | |
| SOMATOTROPINOMA FAMILIAR: RELATO DE 2 CASOS | 2002 | |
| DOENÇA DE CUSHING E HIPERPROLACTINEMIA DEVIDO A MACROADENOMA MISTO PRODUTOR DE ACTH E PROLACTINA | 2002 | |
| AVALIAÇÃO DO RB1 EM ADENOMAS HIPOFISÁRIOS PRODUTORES DE GH ATRAVÉS DE MAPA DE DELEÇÃO TUMORAL DA REGIÃO 13Q12-14 | 2002 | |
| THE GROWTH HORMONE (GH) - AXIS OF GH RECEPTOR/BINDING PROTEIN GENE-DISRUPTED AND METALLOTHIONEIN-HUMAN GH-RELEASING HORMONE TRANSGENIC MICE: HYPOTHALAMIC NEUROPEPTIDE AND PITUITARY RECEPTOR EXPRESSION IN THE ABSENCE AND PRESENCE OF GH FEEDBACK | 2001 | |
| DISFUNÇÃO HORMONAL EM LESÕES NÃO HIPOFISÁRIAS DAS REGIÕES SELAR E PERISELAR | 2001 | |
| NEUROPATIA DIABÉTICA DE EVOLUÇÃO ATÍPICA | 2001 | |
| DIABETES MELLITUS DE DIFÍCIL CONTROLE EM PACIENTE ACROMEGÁLICO - RELATO DE CASO | 2001 | |
| PREVALÊNCIA DE INTOLERÂNCIA À GLICOSE E DIABETES MELLITUS EM ACROMEGÁLICOS NO HUCFF-UFRJ | 2001 | |
| PREVALÊNCIA DE DIABETES MELLITUS E HIPERTENSÃO ARTERIAL SISTÊMICA EM PACIENTES COM SÍNDROME DE CUSHING NO HUCFF-UFRJ | 2001 | |
| ISOLATED FAMILIAL SOMATOTROPINOMAS: ESTABLISHMENT OF LINKAGE TO CHROMOSOME 11Q13.1-11Q13.3 AND EVIDENCE FOR A POTENTIAL SECOND LOCUS AT CHROMOSOME 2P16-12 | 2000 | |
| ISOLATED FAMILIAL SOMATOTROPINOMAS: DOES THE DISEASE MAP TO 11Q13 OR TO 2P16? | 2000 | |
| INTRA-SELLAR SALIVARY GLAND-LIKE PLEOMORPHIC ADENOMA ARISING WITHIN THE WALL OF A RATHKE'S CLEFT CYSTt | 2000 | |
| DIAGNÓSTICO LABORATORIAL DA DEFICIÊNCIA DE HORMÔNIO DE CRESCIMENTO (GH) EM ADULTOS | 2000 | |
| ACROMEGALIA SECUNDÁRIA A SECREÇÃO ECTÓPICA DE HORMÔNIO LIBERADOR DE HORMÔNIO DE CRESCIMENTO (GH-RH) POR TUMOR CARCINÓIDE DE PULMÃO | 2000 | |
| AVALIAÇÃO HORMONAL DAS LESÕES EXPANSIVAS INTRA-CRANIANAS NÃO-HIPOFISÁRIAS | 2000 | |
| ADENOMA CORTICOTRÓFICO SUBCLÍNICO | 2000 | |
| LOSS OF HETEROZYGOSITY ON CHROMOSOME 11Q13 IN TWO FAMILIES WITH ACROMEGALY/GIGANTISM IS INDEPENDENT OF MUTATIONS OF THE MULTIPLE ENDOCRINE NEOPLASIA TYPE I GENE | 1999 | |
| FAMILIAL SOMATOTROPINOMAS: CLINICAL AND GENETIC ASPECTS | 1999 | |
| CAPTAÇÃO DIFERENCIADA DE META-IODOBENZILGUANIDINA EM PACIENTE COM FEOCROMOCITOMA BILATERAL E NEOPLASIA ENDÓCRINA MÚLTIPLA TIPO 2 A | 1999 | |
| COMPLICAÇÕES DAS CIRURGIAS HIPOFISÁRIAS: ANÁLISE DE 120 CIRURGIAS NO HUCFF-UFRJ | 1999 | |
| RELAÇÃO ENTRE O DIAGNÓSTICO CLÍNICO DOS ADENOMAS HIPOFISÁRIOS E IMUNOHISTOQUÍMICA - CASUÍSTICA DOS SERVIÇOS DE ENDOCRINOLOGIA E PATOLOGIA DO HOSPITAL UNIVERSITÁRIO CLEMENTINO FRAGA FILHO - HUCFF-UFRJ | 1999 | |
| ACROMEGALY AND NON-HODGKIN'S LYMPHOMA | 1998 | |
| PSEUDOTUMOR HIPOFISÁRIO SECUNDÁRIO A HIPOTIREOIDISMO PRIMÁRIO | 1998 | |
| ADENOMA CORTICOTRÓFICO SILENCIOSO: RELATO DE CASO | 1997 | |
| SÍNDROME DE KALLMANN | 1997 | |
| DIAGNÓSTICO DIFERENCIAL DAS HIPERPROLACTINEMIAS PATOLÓGICAS | 1997 | |
| REPOSIÇÃO DE HORMÔNIO DE CRESCIMENTO RECOMBINANTE EM ADULTOS COM DÉFICT APÓS CIRURGIA HIPOFISÁRIA | 1996 | |
| ACROMEGALIA FAMILIAR | 1996 | |
| INVESTIGAÇÃO PSICOLÓGICA EM PACIENTES COM DOENÇA DE GRAVES | 1996 | |
| SÍNDROME DE MCCUNE-ALBRIGHT:ATUALIZAÇÃO BIBLIOGRÁFICA E RELATO DE UM CASO. | 1995 | |
| SECREÇÃO E EXPRESSÃO IMUNO-HISTOQUÍMICA DOS HORMÔNIOS HIPOFISÁRIOS E DA SUBUNIDADE ALFA NOS ADENOMAS HIPOFISÁRIOS CLINICAMENTE NÃO FUNCIONANTES | 1995 | |
| TRANSEXUALISMO | 1994 | |
| SÍNDROME POLIGLANDULAR AUTO-IMUNE TIPO II | 1994 | |
| MACROPROLACTINOMA COM REMISSÃO APÓS APOPLEXIA HIPOFISÁRIA | 1994 | |
| ASCITE INTRATÁVEL COMO MANIFESTAÇÃO PRIMÁRIA DE HIPOTIREOIDISMO | 1993 | |
| SÍNDROME DE CUSHING: DISCORDÂNCIA ENTRE A TOMOGRAFIA COMPUTADORIZADA E A CIRURGIA | 1991 | |
| DIABETES INSIPIDUS E GRANULOMA EOSINOFÍLICO | 1991 | |
| MACROADENOMA SECRETOR DE GH E PROLACTINA: RESPOSTA A RADIOTERAPIA HIPOFISÁRIA | 1991 |
Eventos:
(0.00% eventos com DOI)